Literature DB >> 12878586

Formation of high affinity C5 convertase of the classical pathway of complement.

Nenoo Rawal1, Michael K Pangburn.   

Abstract

C3/C5 convertase is a serine protease that cleaves C3 and C5. In the present study we examined the C5 cleaving properties of classical pathway C3/C5 convertase either bound to the surface of sheep erythrocytes or in its free soluble form. Kinetic parameters revealed that the soluble form of the enzyme (C4b,C2a) cleaved C5 at a catalytic rate similar to that of the surface-bound form (EAC1,C4b,C2a). However, both forms of the enzyme exhibited a poor affinity for the substrate, C5, as indicated by a high Km (6-9 microM). Increasing the density of C4b on the cell surface from 8,000 to 172,000 C4b/cell did not influence the Km. Very high affinity C5 convertases were generated only when the low affinity C3/C5 convertases (EAC1,C4b,C2a) were allowed to deposit C3b by cleaving native C3. These C3b-containing C3/C5 convertases exhibited Km (0.0051 microM) well below the normal concentration of C5 in blood (0.37 microM). The data suggest that C3/C5 convertase assembled with either monomeric C4b or C4b-C4b complexes are inefficient in capturing C5 but cleave C3 opsonizing the cell surface with C3b for phagocytosis. Deposition of C3b converts the enzymes to high affinity C5 convertases, which cleave C5 in blood at catalytic rates approaching Vmax, thereby switching from C3 to C5 cleavage. Comparison of the kinetic parameters with those of the alternative pathway convertase indicates that the 6-9-fold greater catalytic rate of the classical pathway C5 convertase may compensate for the fewer numbers of C5 convertase sites generated upon activation of this pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878586     DOI: 10.1074/jbc.M307017200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Immature recent thymic emigrants are eliminated by complement.

Authors:  Fan-Chi Hsu; Michael J Shapiro; Meibo W Chen; Douglas C McWilliams; Lauren M Seaburg; Sarah N Tangen; Virginia Smith Shapiro
Journal:  J Immunol       Date:  2014-11-03       Impact factor: 5.422

2.  The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation.

Authors:  M Harboe; G Ulvund; L Vien; M Fung; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

3.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

4.  Inhibition of the Complement Alternative Pathway by Chemically Modified DNA Aptamers That Bind with Picomolar Affinity to Factor B.

Authors:  Xin Xu; Chi Zhang; Dalton T Denton; Daniel O'Connell; Daniel W Drolet; Brian V Geisbrecht
Journal:  J Immunol       Date:  2021-01-08       Impact factor: 5.422

5.  Structural basis for therapeutic inhibition of complement C5.

Authors:  Matthijs M Jore; Steven Johnson; Devon Sheppard; Natalie M Barber; Yang I Li; Miles A Nunn; Hans Elmlund; Susan M Lea
Journal:  Nat Struct Mol Biol       Date:  2016-03-28       Impact factor: 15.369

6.  Absence of complement component 3 does not prevent classical pathway-mediated hemolysis.

Authors:  Lingjun Zhang; Yang Dai; Ping Huang; Thomas L Saunders; David A Fox; Jijun Xu; Feng Lin
Journal:  Blood Adv       Date:  2019-06-25

7.  Recombinant form of human wild type mannan-binding lectin (MBL/A) but not its structural variant (MBL/C) promotes phagocytosis of zymosan by activating complement.

Authors:  Rema Rajagopalan; Takazvida Nyaundi; Veena P Salvi; Nenoo Rawal
Journal:  Mol Immunol       Date:  2010-06-25       Impact factor: 4.407

8.  Stringent regulation of complement lectin pathway C3/C5 convertase by C4b-binding protein (C4BP).

Authors:  Nenoo Rawal; Rema Rajagopalan; Veena P Salvi
Journal:  Mol Immunol       Date:  2009-08-05       Impact factor: 4.407

9.  Production of Staphylococcal Complement Inhibitor (SCIN) and Other Immune Modulators during the Early Stages of Staphylococcus aureus Biofilm Formation in a Mammalian Cell Culture Medium.

Authors:  Andi R Sultan; Jasper W Swierstra; Nicole A Lemmens-den Toom; Susan V Snijders; Silvie Hansenová Maňásková; Annelies Verbon; Willem J B van Wamel
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

10.  Inhibition of the classical pathway of complement by meningococcal capsular polysaccharides.

Authors:  Sarika Agarwal; Shreekant Vasudhev; Rosane B DeOliveira; Sanjay Ram
Journal:  J Immunol       Date:  2014-07-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.